STOCK TITAN
  1. Home
  2. Sec-filings
  3. AVTX
  4. [Form 4] Avalo Therapeutics, Inc. Insider Trading Activity

Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. (AVTX) reported that its Chief Financial Officer, Christopher Ryan Sullivan, exercised stock options and sold common shares in mid-August 2026. He exercised options to acquire a total of 71,852 shares of common stock at an exercise price of $9.88 per share on August 17 and 18, 2026. Over the same two days, he sold 72,725 shares of common stock in open-market transactions at per-share prices reported around $19.85–$20.05, with specific trades occurring within disclosed ranges. The options exercised were part of grants expiring in 2034 and vesting 25% on March 28, 2025 and monthly thereafter. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Sullivan Christopher Ryan
Role Chief Financial Officer
Sold 72,725 shs ($1.45M)
Approx. gross sale proceeds $1.45M
Approx. exercise cost $710K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F5 31,031 $0.00 $0.00
Exercise Common Stock 31,031 $9.88 $307K
Sale Common Stock F4 31,031 $20.0549 $622K
Exercise Stock Option (Right to Buy) F1, F5 37,945 $0.00 $0.00
Exercise Stock Option (Right to Buy) F5 2,876 $0.00 $0.00
Exercise Common Stock F1 37,945 $9.88 $375K
Exercise Common Stock 2,876 $9.88 $28K
Sale Common Stock F1, F2 37,945 $19.8533 $753K
Sale Common Stock F3 3,749 $19.9419 $75K
Holdings After Transaction: Stock Option (Right to Buy) — 96,242 shares (Direct); Common Stock — 39,900 shares (Direct)
Footnotes (5)
  1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
  2. F2. The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3. The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. F4. The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  5. F5. The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
Total shares sold 72,725 shares Common stock sales reported on August 17–18, 2026
Total shares acquired via exercise 71,852 shares Common stock acquired from stock option exercises on August 17–18, 2026
Option exercise price $9.88 per share Exercise price for stock options converted into common stock
Sale price example 1 $19.8533 per share Per-share price reported for a 37,945-share sale on August 17, 2026
Sale price example 2 $19.9419 per share Per-share price reported for a 3,749-share sale on August 17, 2026
Sale price example 3 $20.0549 per share Per-share price reported for a 31,031-share sale on August 18, 2026
Option expiration August 13, 2034 Expiration date for the stock options exercised
10b5-1 plan adoption date May 18, 2026 Adoption date of the Rule 10b5-1 trading plan referenced in the footnote
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
derivative security financial
"transaction_type: derivative and transaction_code_description text"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

What insider transactions did AVTX CFO Christopher Ryan Sullivan report on this Form 4?
Christopher Ryan Sullivan reported exercising stock options for 71,852 AVTX shares at $9.88 per share and selling 72,725 common shares in market transactions on August 17–18, 2026 under a Rule 10b5-1 trading plan.

At what prices were the AVTX shares sold in the reported insider transactions?
The reported AVTX shares were sold at per-share prices around $19.85–$20.05, within ranges of $19.16–$20.02, $19.70–$20.02, and $20.00–$20.265, according to the footnotes describing multiple transaction price bands.

How many Avalo Therapeutics (AVTX) shares did the CFO acquire through option exercises?
Through option exercises, the CFO acquired 71,852 shares of AVTX common stock on August 17–18, 2026 at an exercise price of $9.88 per share, converting derivative stock options into common stock.

Were the AVTX insider trades made under a Rule 10b5-1 trading plan?
Yes. The filing indicates all reported AVTX transactions were effected pursuant to a Rule 10b5-1 trading plan, with a footnote stating the plan was adopted by the reporting person on May 18, 2026.

What stock option terms are disclosed for the AVTX CFO’s exercised options?
The exercised AVTX stock options had an exercise price of $9.88 per share, an expiration date of August 13, 2034, and a vesting schedule of 25% on March 28, 2025, with the remainder vesting in 1/36 monthly installments thereafter.

How many AVTX shares did the CFO sell in these insider transactions?
The CFO reported selling 72,725 shares of Avalo Therapeutics common stock across three sale transactions on August 17–18, 2026, with prices reported in specified ranges around $20 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sullivan Christopher Ryan
(Last)(First)(Middle)
C/O AVALO THERAPEUTICS, INC.
1500 LIBERTY RIDGE DRIVE, SUITE 321
(Street)
WAYNE PENNSYLVANIA 19087
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/17/2026M(1)37,945A$9.8878,718D
Common Stock08/17/2026M2,876A$9.8881,594D
Common Stock08/17/2026S(1)37,945D$19.8533(2)43,649D
Common Stock08/17/2026S3,749D$19.9419(3)39,900D
Common Stock08/18/2026M31,031A$9.8870,931D
Common Stock08/18/2026S31,031D$20.0549(4)39,900D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$9.8808/17/2026M(1)37,945 (5)08/13/2034Common Stock37,945$0130,149D
Stock Option (Right to Buy)$9.8808/17/2026M2,876 (5)08/13/2034Common Stock2,876$0127,273D
Stock Option (Right to Buy)$9.8808/18/2026M31,031 (5)08/13/2034Common Stock31,031$096,242D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
2. The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
3. The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
4. The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
5. The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
/s/ Christopher Sullivan08/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR